Nordic Nanovector has announced that the first cohorts of both Arm 3 and 4 of the expanded Lymrit 37-01 clinical study with Betalutin have been completed.
Betalutin is an anti-CD37 targeting Antibody Radionuclide Conjugate to treat major types of non-hodgkin lymphoma (NHL), including Follicular Lymphoma (FL).
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Arm 3 is probing the safety and efficacy of Betalutin in relapsed FL patients who have been pre-dosed with standard anti-CD20 immunotherapy (rituximab) on Day 0, just a few hours before the administration of 15 megabecquerel / kilograms (MBq/kg) of Betalutin.
Arm 4 is analysing the safety and efficacy of Betalutin in relapsed FL patients pre-dosed with high-dose unconjugated 'cold' lilotomab, previously known as HH1, anti-CD37 antibody on Day 0, a few hours before the administration of 15MBq/kg Betalutin.
Nordic Nanovector CEO Luigi Costa said: “We are pleased to have completed the first cohorts of both Arm III and Arm IV of the expanded Lymrit 37-01 study.
“These arms are designed to investigate if different pre-dosing regimens will allow the use of higher doses of Betalutin to potentially achieve even better efficacy and an even more compelling product profile.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“The role of pre-dosing is to potentially ensure better control of haematological side effects and more specific tumour targeting with Betalutin.”
A decision to raise the dose of Betalutin to 17.5MBq/kg or 20MBq/kg in one or the other arm can be taken based on the analysis of the safety and efficacy data observed in these first three patients of both arms.
The Lymrit 37-01 study is a Phase 1/2 open label, single injection ascending dose study investigating three dose levels of Betalutin and different pre-dosing regimens in patients with relapsed NHL.
The aim of this study is to identify an optimal dose regimen to be taken in the Phase 2 PARADIGME study, expected to commence in the second half of 2017.
